| 000 | 01664 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514210640.0 | ||
| 264 | 0 | _c20050317 | |
| 008 | 200503s 0 0 eng d | ||
| 022 | _a0300-7995 | ||
| 024 | 7 |
_a10.1185/030079904X5959 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDonnenfeld, Eric | |
| 245 | 0 | 0 |
_aA comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. _h[electronic resource] |
| 260 |
_bCurrent medical research and opinion _cNov 2004 |
||
| 300 |
_a1753-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnterior Chamber _xdrug effects |
| 650 | 0 | 4 |
_aAza Compounds _xtoxicity |
| 650 | 0 | 4 |
_aConjunctiva _xdrug effects |
| 650 | 0 | 4 |
_aEye _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluoroquinolones _xtoxicity |
| 650 | 0 | 4 | _aGatifloxacin |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperemia _xchemically induced |
| 650 | 0 | 4 | _aIrritants |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMoxifloxacin |
| 650 | 0 | 4 |
_aOphthalmic Solutions _xtoxicity |
| 650 | 0 | 4 |
_aPain _xchemically induced |
| 650 | 0 | 4 |
_aPupil _xdrug effects |
| 650 | 0 | 4 |
_aQuinolines _xtoxicity |
| 700 | 1 | _aPerry, Henry D | |
| 700 | 1 | _aChruscicki, Daniel A | |
| 700 | 1 | _aBitterman, Adam | |
| 700 | 1 | _aCohn, Stephanie | |
| 700 | 1 | _aSolomon, Renée | |
| 773 | 0 |
_tCurrent medical research and opinion _gvol. 20 _gno. 11 _gp. 1753-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1185/030079904X5959 _zAvailable from publisher's website |
| 999 |
_c15224760 _d15224760 |
||